| 1 |
Giampaoli O, Sciubba F, Biliotti E, Spagnoli M, Calvani R, Tomassini A, Capuani G, Miccheli A, Taliani G. Precision Medicine: Determination of Ribavirin Urinary Metabolites in Relation to Drug Adverse Effects in HCV Patients. Int J Mol Sci 2022;23:10043. [PMID: 36077436 DOI: 10.3390/ijms231710043] [Reference Citation Analysis]
|
| 2 |
Lee Y, Jang EJ, Yoon HY, Yee J, Gwak HS. Effect of ITPA Polymorphism on Adverse Drug Reactions of 6-Mercaptopurine in Pediatric Patients with Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel) 2022;15. [PMID: 35455413 DOI: 10.3390/ph15040416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Salam AP, Duvignaud A, Jaspard M, Malvy D, Carroll M, Tarning J, Olliaro PL, Horby PW. Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing. PLoS Negl Trop Dis 2022;16:e0010289. [PMID: 35353804 DOI: 10.1371/journal.pntd.0010289] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 4 |
Tammam SN, El Safy S, Ramadan S, Arjune S, Krakor E, Mathur S. Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2. J Control Release 2021;337:258-84. [PMID: 34293319 DOI: 10.1016/j.jconrel.2021.07.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 5 |
Liatsos GD. Controversies’ clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages. World J Clin Cases 2021; 9(19): 5135-5178 [PMID: 34307564 DOI: 10.12998/wjcc.v9.i19.5135] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 6 |
Lapumnuaypol K, Pisarcik D, Putthapiban P, Sukhumthammarat W, Wijarnpreecha K, Thongprayoon C, Ungprasert P. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis. Indian J Med Res 2020;152:562-7. [PMID: 34145095 DOI: 10.4103/ijmr.IJMR_1088_18] [Reference Citation Analysis]
|
| 7 |
Zhu J, Li Q, Yu X, Zhang X, Li H, Wen K, Ke Y, Zhang S, Wang Z. Synthesis of hapten, production of monoclonal antibody, and development of immunoassay for ribavirin detection in chicken. J Food Sci 2021;86:2851-60. [PMID: 34146404 DOI: 10.1111/1750-3841.15789] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 8 |
Bianco C, Coluccio E, Prati D, Valenti L. Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders. J Clin Med 2021;10:423. [PMID: 33499290 DOI: 10.3390/jcm10030423] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Abo-Zeid Y, Williams GR, Touabi L, McLean GR. An investigation of rhinovirus infection on cellular uptake of poly (glycerol-adipate) nanoparticles. Int J Pharm 2020;589:119826. [PMID: 32871219 DOI: 10.1016/j.ijpharm.2020.119826] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 10 |
Papadopoulos C, Panopoulou M, Mylopoulou T, Mimidis K, Tentes I, Anagnostopoulos K. Cholesterol and Phospholipid Distribution Pattern in the Erythrocyte Membrane of Patients with Hepatitis C and Severe Fibrosis, before and after Treatment with Direct Antiviral Agents: A pilot Study. Maedica (Bucur) 2020;15:162-8. [PMID: 32952679 DOI: 10.26574/maedica.2020.15.2.162] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 11 |
Craxi A. EASL Recognition Awardee 2020: Prof. Giovanna Fattovich. J Hepatol 2020;73:484-6. [PMID: 32807366 DOI: 10.1016/j.jhep.2020.02.003] [Reference Citation Analysis]
|
| 12 |
Wahid B. Clinical Correlation of Blood Cells with Suppression of Cytokine Signaling Gene Expression in Hepatitis C Virus-Infected Patients. J Interferon Cytokine Res 2020;40:169-71. [PMID: 31985329 DOI: 10.1089/jir.2019.0116] [Reference Citation Analysis]
|
| 13 |
Wang Y, Zhu LQ. Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019. World J Pediatr 2020;16:271-4. [PMID: 32166483 DOI: 10.1007/s12519-020-00353-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 46] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 14 |
Kwon JE, Lee Y, Kang J, Bai Y, Jeong YJ, Baek N, Seo Y, Kang SC. Anti-viral activity of compounds from Agrimonia pilosa and Galla rhois extract mixture. Bioorganic Chemistry 2019;93:103320. [DOI: 10.1016/j.bioorg.2019.103320] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 15 |
Bhattacharya S, Dhar S, Banerjee A, Ray S. Detailed Molecular Biochemistry for Novel Therapeutic Design Against Nipah and Hendra Virus: A Systematic Review. Curr Mol Pharmacol 2020;13:108-25. [PMID: 31657692 DOI: 10.2174/1874467212666191023123732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 16 |
Inomata S, Anan A, Yamauchi E, Yamauchi R, Kunimoto H, Takata K, Tanaka T, Yokoyama K, Morihara D, Takeyama Y, Irie M, Shakado S, Sohda T, Sakisaka S. Changes in the Serum Hepcidin-to-ferritin Ratio with Erythroferrone after Hepatitis C Virus Eradication Using Direct-acting Antiviral Agents. Intern Med 2019;58:2915-22. [PMID: 31243222 DOI: 10.2169/internalmedicine.2909-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Supramaniam A, Bielefeldt-Ohmann H, Rudd PA, Webster J, Ferro V, Herrero LJ. PG545 treatment reduces RRV-induced elevations of AST, ALT with secondary lymphoid organ alterations in C57BL/6 mice. PLoS One 2019;14:e0217998. [PMID: 31170255 DOI: 10.1371/journal.pone.0217998] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 18 |
Doyle MA, Galanakis C, Mulvihill E, Crawley A, Cooper CL. Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters. Cells 2019;8:E252. [PMID: 30884773 DOI: 10.3390/cells8030252] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 19 |
Ruiz I, Pawlotsky JM. Hepatitis B Reactivation or Hepatitis C Exacerbation in Patients with Hematological Malignancies. Ann Hepatol 2017;16:179-81. [PMID: 28233738 DOI: 10.5604/16652681.1231595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 20 |
Nyström K, Waldenström J, Tang K, Lagging M. Ribavirin: pharmacology, multiple modes of action and possible future perspectives. Future Virology 2019;14:153-60. [DOI: 10.2217/fvl-2018-0166] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 21 |
Sato S, Moriya K, Furukawa M, Saikawa S, Namisaki T, Kitade M, Kawaratani H, Kaji K, Takaya H, Shimozato N, Sawada Y, Seki K, Kitagawa K, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H. Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection. Clin Mol Hepatol 2019;25:65-73. [PMID: 30798587 DOI: 10.3350/cmh.2018.0070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 22 |
Altintas E, Yalin S, Sezgin O, Ucbilek E, Tombak A, Kanik A. Erythrocyte Membrane Protein Band 3 Predicts Interferon Ribavirin-Induced Anemia. OJRM 2019;08:5-16. [DOI: 10.4236/ojrm.2019.82002] [Reference Citation Analysis]
|
| 23 |
Farooq M, Mumtaz SU, Akhtar H, Ashraf K, Komal T, Qureshi IH. Frequency of Hypothyroidism in Chronic Hepatitis C patients treated with Standard Interferon Therapy. PBMJ 2019;1. [DOI: 10.52229/pbmj.v1i2.46] [Reference Citation Analysis]
|
| 24 |
Alqahtani SA, Sulkowski MS. The Role of Interferon for the Treatment of Chronic Hepatitis C Virus Infection. Topics in Medicinal Chemistry 2019. [DOI: 10.1007/7355_2018_59] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 25 |
Nyström K, Wanrooij PH, Waldenström J, Adamek L, Brunet S, Said J, Nilsson S, Wind-Rotolo M, Hellstrand K, Norder H, Tang KW, Lagging M. Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus. J Virol 2018;92:e01087-18. [PMID: 30045981 DOI: 10.1128/JVI.01087-18] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 26 |
Feld JJ, Bernstein DE, Younes Z, Vlierberghe HV, Larsen L, Tatsch F, Ferenci P. Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. Liver Int 2018;38:1571-5. [PMID: 29377566 DOI: 10.1111/liv.13708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 27 |
Vasanthakumar A, Davis JW, Abunimeh M, Söderholm J, Zha J, Dumas EO, Cohen DE, Waring JF, Lagging M. Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens. PLoS One 2018;13:e0198296. [PMID: 29851985 DOI: 10.1371/journal.pone.0198296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 28 |
Collas O, Robertson FP, Fuller BJ, Davidson BR. Anaemia in patients with chronic liver disease and its association with morbidity and mortality following liver transplantation. International Journal of Surgery 2018;53:48-52. [DOI: 10.1016/j.ijsu.2018.02.053] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 29 |
Tanaka Y, Yokomori H, Otori K. Induction of inosine triphosphatase activity during ribavirin treatment for chronic hepatitis C. Clin Chim Acta 2018;482:16-20. [PMID: 29580856 DOI: 10.1016/j.cca.2018.03.018] [Reference Citation Analysis]
|
| 30 |
De Winter BCM, Hesselink DA, Kamar N. Dosing ribavirin in hepatitis E-infected solid organ transplant recipients. Pharmacol Res 2018;130:308-15. [PMID: 29499270 DOI: 10.1016/j.phrs.2018.02.030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 31 |
Patel YA, Kappus MR, Muir AJ. Anemia in Liver Disease. Management of Anemia 2018. [DOI: 10.1007/978-1-4939-7360-6_7] [Reference Citation Analysis]
|
| 32 |
Cobb AJA, Dell’isola A, Abdulsattar BO, Mclachlan MMW, Neuman BW, Müller C, Shankland K, Al-mulla HMN, Binks AWD, Elvidge W. Synthesis and antiviral activity of novel spirocyclic nucleosides. New J Chem 2018;42:18363-80. [DOI: 10.1039/c8nj02777c] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 33 |
Prasad N, Patel MR, Pandey A, Jaiswal A, Bhadauria D, Kaul A, Sharma RK, Mohindra S, Pandey G, Goel A, Gupta A. Direct-acting Antiviral Agents in Hepatitis C Virus-infected Renal Allograft Recipients: Treatment and Outcome Experience from Single Center. Indian J Nephrol 2018;28:220-5. [PMID: 29962673 DOI: 10.4103/ijn.IJN_190_17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 34 |
Liang PC, Lin PC, Huang CI, Huang CF, Yeh ML, Zeng YS, Hsu WY, Hsieh MY, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chiou SS, Yu ML. The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C. J Formos Med Assoc 2018;117:14-23. [PMID: 29097076 DOI: 10.1016/j.jfma.2017.10.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 35 |
Fried MW, Darling JM, Lemon SM. Hepatitis C. Schiff's Diseases of the Liver 2017. [DOI: 10.1002/9781119251316.ch25] [Reference Citation Analysis]
|
| 36 |
Smolić M, Omanović T, Božić I, Bilić-ćurčić I, Smolić R, Včev A. Pharmacogenomic Testing in the Era of Patient-Tailored HCV Treatment. Update on Hepatitis C 2017. [DOI: 10.5772/intechopen.70794] [Reference Citation Analysis]
|
| 37 |
Handala L, Domange B, Ouled-Haddou H, Garçon L, Nguyen-Khac E, Helle F, Bodeau S, Duverlie G, Brochot E. DHEA prevents ribavirin-induced anemia via inhibition of glucose-6-phosphate dehydrogenase. Antiviral Res 2017;146:153-60. [PMID: 28890388 DOI: 10.1016/j.antiviral.2017.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 38 |
Liu Z, Wang S, Qi W, Wang X, Sun D, Wang H, Zhang Y, Li Z, Zhu L, Zhao P, Guo H, Zhou C, Wang J. The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients. Medicine (Baltimore) 2017;96:e7554. [PMID: 28723780 DOI: 10.1097/MD.0000000000007554] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 39 |
Molina-Cuadrado E, Mateo-Carrrasco H, Collado A, Casado Martín M. Anaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents. Eur J Hosp Pharm 2018;25:132-7. [PMID: 31157007 DOI: 10.1136/ejhpharm-2017-001277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 40 |
Gonzalez-Aldaco K, Rebello Pinho JO, Panduro A, Martinez-Lopez E, Gleyzer K, Fierro N, Roman S. High Prevalence of ITPA Alleles Associated with Ribavirin-Induced Hemolytic Anemia Among Mexican Population. Ann Hepatol 2017;16:221-9. [PMID: 28233743 DOI: 10.5604/16652681.1231582] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 41 |
Lee DU, Je SH, Yoo SJ, Kwon T, Shin JY, Byun JJ, Park JH, Jeong KW, Ku JM, Lyoo YS. Hematological adverse effects and pharmacokinetics of ribavirin in pigs following intramuscular administration. J Vet Pharmacol Ther 2017;40:561-8. [PMID: 28205288 DOI: 10.1111/jvp.12394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 42 |
Dzekova-Vidimliski P, Sikole A. Hepatitis C virus infection in maintenance hemodialysis patients: recommendations for diagnostics and treatment. Int J Artif Organs 2017;39:590-5. [PMID: 28165585 DOI: 10.5301/ijao.5000548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 43 |
Jimmerson LC, Clayton CW, MaWhinney S, Meissner EG, Sims Z, Kottilil S, Kiser JJ. Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines. Antiviral Res 2017;138:79-85. [PMID: 27956135 DOI: 10.1016/j.antiviral.2016.12.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 44 |
Bodeau S, Lemouel JP, Diouf M, Duverlie G, Nguyen-Khac E, Brochot E. Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEA. J Med Virol 2017;89:1033-9. [PMID: 27805268 DOI: 10.1002/jmv.24726] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 45 |
Santos AED, Partovi N, Ford JE, Yoshida EM. Use of Hematopoietic Growth Factors as Adjuvant Therapy for Anemia and Neutropenia in the Treatment of Hepatitis C. Ann Pharmacother 2007;41:268-75. [DOI: 10.1345/aph.1h169] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 46 |
Burgis NE. A disease spectrum for ITPA variation: advances in biochemical and clinical research. J Biomed Sci 2016;23:73. [PMID: 27770805 DOI: 10.1186/s12929-016-0291-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 47 |
Jimmerson LC, Bushman LR, Ray ML, Anderson PL, Kiser JJ. A LC-MS/MS Method for Quantifying Adenosine, Guanosine and Inosine Nucleotides in Human Cells. Pharm Res 2017;34:73-83. [PMID: 27633886 DOI: 10.1007/s11095-016-2040-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 48 |
Wynter J, Stine JG, Shah NL. Chronic hepatitis C and diabetes: More questions than answers with the new direct acting antiviral drugs? Dig Liver Dis 2016;48:1101. [PMID: 27257048 DOI: 10.1016/j.dld.2016.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 49 |
Ampuero J, Romero-Gómez M. Pharmacogenetics of ribavirin-induced anemia in hepatitis C. Pharmacogenomics 2016;17:1587-94. [PMID: 27547881 DOI: 10.2217/pgs.16.28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 50 |
Ma YJ, Zhang HD, Wu CH, Zhu GL, Ji YQ, Huang JL, Du LT, Cao P, Zang DY, Ji KM. Rapid CO breath test screening of drugs for protective effects on ribavirin-induced hemolysis in a rabbit model: a pilot study. J Breath Res 2016;10:036010. [PMID: 27506143 DOI: 10.1088/1752-7155/10/3/036010] [Reference Citation Analysis]
|
| 51 |
Jimmerson LC, Urban TJ, Truesdale A, Baouchi-Mokrane F, Kottilil S, Meissner EG, Sims Z, Langness JA, Hodara A, Aquilante CL, Kiser JJ. Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels. J Clin Pharmacol 2017;57:118-24. [PMID: 27349952 DOI: 10.1002/jcph.783] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 52 |
Pham YH, Rosenthal P. Chronic Hepatitis C Infection in Children. Adv Pediatr 2016;63:173-94. [PMID: 27426900 DOI: 10.1016/j.yapd.2016.04.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 53 |
Mei R, Chi X, Wu R, Xu H, Wang X, Gao X, Sun H, Lv J, Yu G, Kong F, Jiang J, Sun B, Zhong J, Pan Y, Niu J. Sustained viral response and treatment-induced cytopenia correlate with SLCs and KLF12 genotypes in interferon/ribavirin-treated Chinese chronic hepatitis C patients. J Gastroenterol Hepatol 2016;31:1489-97. [PMID: 26750805 DOI: 10.1111/jgh.13290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 54 |
Ghezzi P, Ungheri D. Synergistic Combination of N-Acetylcysteine and Ribavirin to Protect from Lethal Influenza Viral Infection in a Mouse Model. Int J Immunopathol Pharmacol 2004;17:99-102. [DOI: 10.1177/039463200401700114] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 55 |
Danial M, Andersen AHF, Zuwala K, Cosson S, Riber CF, Smith AAA, Tolstrup M, Moad G, Zelikin AN, Postma A. Triple Activity of Lamivudine Releasing Sulfonated Polymers against HIV-1. Mol Pharmaceutics 2016;13:2397-410. [DOI: 10.1021/acs.molpharmaceut.6b00156] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 56 |
D'Avolio A, Cusato J, De Nicolò A, Allegra S, Di Perri G. Pharmacogenetics of ribavirin-induced anemia in HCV patients. Pharmacogenomics 2016;17:925-41. [PMID: 27248282 DOI: 10.2217/pgs.16.22] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 57 |
Waldenström J, Westin J, Nyström K, Christensen P, Dalgard O, Färkkilä M, Lindahl K, Nilsson S, Norkrans G, Krarup H, Norrgren H, Rauning Buhl M, Stenmark S, Lagging M. Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. PLoS One 2016;11:e0155142. [PMID: 27167219 DOI: 10.1371/journal.pone.0155142] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 58 |
Shuldiner SR, Gong L, Muir AJ, Altman RB, Klein TE. PharmGKB summary: peginterferon-α pathway. Pharmacogenet Genomics 2015;25:465-74. [PMID: 26111151 DOI: 10.1097/FPC.0000000000000158] [Reference Citation Analysis]
|
| 59 |
Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 49] [Cited by in F6Publishing: 63] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 60 |
San Martín B, Muñoz R, Cornejo J, Martínez MA, Araya-Jordán C, Maddaleno A, Anadón A. Pharmacokinetics, efficacy prediction indexes, and residue depletion of ribavirin in Atlantic salmon's (Salmo salar) muscle after oral administration in feed. J Vet Pharmacol Ther 2016;39:388-97. [PMID: 26960624 DOI: 10.1111/jvp.12288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 61 |
Amly W, Karaman R. Recent updates in utilizing prodrugs in drug delivery (2013-2015). Expert Opin Drug Deliv 2016;13:571-91. [PMID: 26785610 DOI: 10.1517/17425247.2016.1142527] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 62 |
Wu LS, Jimmerson LC, MacBrayne CE, Kiser JJ, D'Argenio DZ. Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus. CPT Pharmacometrics Syst Pharmacol 2016;5:65-73. [PMID: 26933517 DOI: 10.1002/psp4.12058] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 63 |
Lupo F, Russo R, Iolascon A, Ieluzzi D, Siciliano A, Toniutto P, Matté A, Piovesan S, Raffetti E, Turrini F, Dissegna D, Donato F, Alberti A, Zuliani V, Fattovich G, De Franceschi L. Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients. Liver Int 2016;36:49-58. [PMID: 26104535 DOI: 10.1111/liv.12900] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 64 |
Nagamine T, Sato K, Kakizaki S, Satoh T, Koka M, Kamiya T. Analysis of Erythrocyte Elements in Chronic Hepatitis C Patients Receiving PegIFN Monotherapy, Dual Therapy, and Triple Therapy using in-air MicroPIXE. kmj 2016;66:91-102. [DOI: 10.2974/kmj.66.91] [Reference Citation Analysis]
|
| 65 |
Ribavirin. Meyler's Side Effects of Drugs 2016. [DOI: 10.1016/b978-0-444-53717-1.01403-7] [Reference Citation Analysis]
|
| 66 |
Nemr N, Kishk R, Mandour M. Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C. Indian J Gastroenterol 2016;35:7-13. [PMID: 26880169 DOI: 10.1007/s12664-016-0618-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 67 |
Hwang JJ, Lo CC, Lin CH, Cheng HS, Hung IW, Tsai WJ, Hung CH. Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy. Gut Liver 2015;9:214-23. [PMID: 25287171 DOI: 10.5009/gnl14095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 68 |
Cusato J, Allegra S, Boglione L, De Nicolò A, Cariti G, Di Perri G, D'Avolio A. VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. Pharmacogenet Genomics 2015;25:164-72. [PMID: 25713999 DOI: 10.1097/FPC.0000000000000123] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 69 |
Pineda-Tenor D, García-Álvarez M, Jiménez-Sousa MA, Vázquez-Morón S, Resino S. Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis. J Transl Med 2015;13:320. [PMID: 26438033 DOI: 10.1186/s12967-015-0682-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 70 |
Bordbar A, Mccloskey D, Zielinski D, Sonnenschein N, Jamshidi N, Palsson B. Personalized Whole-Cell Kinetic Models of Metabolism for Discovery in Genomics and Pharmacodynamics. Cell Systems 2015;1:283-92. [DOI: 10.1016/j.cels.2015.10.003] [Cited by in Crossref: 75] [Cited by in F6Publishing: 60] [Article Influence: 9.4] [Reference Citation Analysis]
|
| 71 |
D’ambrosio R, Poggiali E, Cappellini MD. Treating hepatitis C in patients with hemoglobinopathies. Expert Opinion on Orphan Drugs 2015;3:1267-78. [DOI: 10.1517/21678707.2015.1086333] [Reference Citation Analysis]
|
| 72 |
Coppola N, Pisaturo M, Sagnelli C, Onorato L, Sagnelli E. Role of genetic polymorphisms in hepatitis C virus chronic infection. World J Clin Cases 2015; 3(9): 807-822 [PMID: 26380828 DOI: 10.12998/wjcc.v3.i9.807] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 73 |
Balk JM, Haenen GR, Koc ÖM, Peters R, Bast A, van der Vijgh WJ, Koek GH. Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial. Pharmgenomics Pers Med 2015;8:137-44. [PMID: 26445557 DOI: 10.2147/PGPM.S82782] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 74 |
Rembeck K, Lagging M. Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection. Pharmacogenomics 2015;16:1179-88. [PMID: 26250055 DOI: 10.2217/pgs.15.65] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 75 |
Hung AK, Guy J, Behler CM, Lee EE. Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation. Case Rep Transplant 2015;2015:286276. [PMID: 26240773 DOI: 10.1155/2015/286276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 76 |
Guo H, Sun S, Yang Z, Tang X, Wang Y. Strategies for ribavirin prodrugs and delivery systems for reducing the side-effect hemolysis and enhancing their therapeutic effect. Journal of Controlled Release 2015;209:27-36. [DOI: 10.1016/j.jconrel.2015.04.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 77 |
Hesari AK, Shahrooz R, Ahmadi A, Malekinejad H, Saboory E. Crocin prevention of anemia-induced changes in structural and functional parameters of mice testes. J Appl Biomed 2015;13:213-23. [DOI: 10.1016/j.jab.2015.02.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 78 |
Naing C, Sitt T, Aung AT, Aung K. Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study. Medicine (Baltimore) 2015;94:e1234. [PMID: 26222859 DOI: 10.1097/MD.0000000000001234] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 79 |
Kogiso T, Tokushige K, Hashimoto E, Taniai M, Omori A, Kotera Y, Egawa H, Yamamoto M, Shiratori K. Mycophenolate mofetil may induce prolonged severe anemia during pegylated-interferon/ribavirin/simeprevir therapy in liver transplant recipients. Clin J Gastroenterol. 2015;8:156-161. [PMID: 25963122 DOI: 10.1007/s12328-015-0570-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 80 |
Kucherenko A, Pampukha V, Bobrova I, Moroz L, Livshits L. ITPA gene variant may protect against anemia induced during pegylated interferon Alfa and Ribavirin combination treatment in Ukrainian patients with chronic hepatitis C. Cytol Genet 2015;49:109-12. [DOI: 10.3103/s009545271502005x] [Reference Citation Analysis]
|
| 81 |
Bunchorntavakul C, Maneerattanaporn M, Chavalitdhamrong D. Management of patients with hepatitis C infection and renal disease. World J Hepatol 2015;7:213-25. [PMID: 25729476 DOI: 10.4254/wjh.v7.i2.213] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 82 |
Bodeau S, Nguyen-Khac E, Solas C, Bennis Y, Capron D, Duverlie G, Brochot E. Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations. J Clin Pharmacol 2015;55:517-24. [PMID: 25535910 DOI: 10.1002/jcph.454] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 83 |
Wu LS, Rower JE, Burton JR Jr, Anderson PL, Hammond KP, Baouchi-Mokrane F, Everson GT, Urban TJ, D'Argenio DZ, Kiser JJ. Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 2015;59:2179-88. [PMID: 25645847 DOI: 10.1128/AAC.04618-14] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 84 |
Dong Z, Li Q, Guo D, Shu Y, Polli JE. Synthesis and Evaluation of Bile Acid-Ribavirin Conjugates as Prodrugs to Target the Liver. J Pharm Sci 2015;104:2864-76. [PMID: 25645375 DOI: 10.1002/jps.24375] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 85 |
Carvalho-Filho RJ, Feldner ACC, Silva AEB, Ferraz MLG. Management of hepatitis C in patients with chronic kidney disease. World J Gastroenterol 2015; 21(2): 408-422 [PMID: 25593456 DOI: 10.3748/wjg.v21.i2.408] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 86 |
Laouénan C, Guedj J, Peytavin G, Nguyen TT, Lapalus M, Khelifa-Mouri F, Boyer N, Zoulim F, Serfaty L, Bronowicki JP, Martinot-Peignoux M, Lada O, Asselah T, Dorival C, Hézode C, Carrat F, Nicot F, Marcellin P, Mentré F. A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy. CPT Pharmacometrics Syst Pharmacol 2015;4:e00008. [PMID: 26225222 DOI: 10.1002/psp4.8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 87 |
de Kanter CT, Drenth JP, Arends JE, Reesink HW, van der Valk M, de Knegt RJ, Burger DM. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2014;53:409-27. [PMID: 24723109 DOI: 10.1007/s40262-014-0142-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 88 |
Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S; EMERGE study group. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol 2014;61:1238-46. [PMID: 25064437 DOI: 10.1016/j.jhep.2014.07.022] [Cited by in Crossref: 105] [Cited by in F6Publishing: 107] [Article Influence: 11.7] [Reference Citation Analysis]
|
| 89 |
Serranti D, Indolfi G, Resti M. New treatments for chronic hepatitis C: An overview for paediatricians. World J Gastroenterol 2014; 20(43): 15965-15974 [PMID: 25473150 DOI: 10.3748/wjg.v20.i43.15965] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 90 |
Savic D, Stojiljkovic M, Lavrnja I, Parabucki A, Bjelobaba I, Nedeljkovic N, Herdegen T, Pekovic S. Ribavirin shows immunomodulatory effects on activated microglia. Immunopharmacology and Immunotoxicology 2014;36:433-41. [DOI: 10.3109/08923973.2014.971962] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 91 |
Trinks J, Hulaniuk ML, Redal MA, Flichman D. Clinical utility of pharmacogenomics in the management of hepatitis C. Pharmgenomics Pers Med 2014;7:339-47. [PMID: 25382982 DOI: 10.2147/PGPM.S52624] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 92 |
Saab S, Jackson C, Nieto J, Francois F. Hepatitis C in African Americans. Am J Gastroenterol 2014;109:1576-84; quiz 1575, 1585. [PMID: 25178700 DOI: 10.1038/ajg.2014.243] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 93 |
Amanzada A, Goralczyk AD, Reinhardt L, Moriconi F, Cameron S, Mihm S. Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy. BMC Infect Dis 2014;14:503. [PMID: 25227310 DOI: 10.1186/1471-2334-14-503] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 94 |
De Nicolò A, Boglione L, Ciancio A, Cusato J, Strona S, Cardellino CS, Mohamed Abdi A, Cariti G, Troshina G, Caviglia GP, Smedile A, Rizzetto M, Di Perri G, D’avolio A. Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. Antiviral Research 2014;109:7-14. [DOI: 10.1016/j.antiviral.2014.06.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 95 |
Quiles-pérez R, Pavón-castillero EJ, Muñoz-de-rueda P, Carmona I, Salmerón J. Valor de la genética en la era de la terapia triple frente al virus de la hepatitis C. Gastroenterología y Hepatología 2014;37:427-37. [DOI: 10.1016/j.gastrohep.2014.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 96 |
Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2014;20:89-136. [PMID: 25032178 DOI: 10.3350/cmh.2014.20.2.89] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 97 |
Ronzoni L, Aghemo A, Rumi MG, Prati G, Colancecco A, Porretti L, Monico S, Colombo M, Cappellini MD. Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients. J Viral Hepat 2014;21:416-23. [PMID: 24750239 DOI: 10.1111/jvh.12158] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 98 |
Stättermayer AF, Scherzer T, Beinhardt S, Rutter K, Hofer H, Ferenci P. Review article: genetic factors that modify the outcome of viral hepatitis. Aliment Pharmacol Ther 2014;39:1059-70. [PMID: 24654629 DOI: 10.1111/apt.12717] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 99 |
Boglione L, De Nicolò A, Cusato J, Cariti G, Di Perri G, D'Avolio A. Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. J Viral Hepat 2014;21:260-3. [PMID: 24597694 DOI: 10.1111/jvh.12170] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 100 |
Brochot E, Bodeau S, Nguyen-Khac E, Duverlie G. DHEA and progesterone have a protective effect on ribavirin-induced hemolysis. J Hepatol 2014;60:897-8. [PMID: 24412434 DOI: 10.1016/j.jhep.2013.11.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 101 |
Gatselis NK, Zachou K, Saitis A, Samara M, Dalekos GN. Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol 2014; 20(11): 2839-2853 [PMID: 24659876 DOI: 10.3748/wjg.v20.i11.2839] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 102 |
Ridruejo E. Safety of direct-acting antivirals in the treatment of chronic hepatitis C. Expert Opin Drug Saf 2014;13:307-19. [PMID: 24547916 DOI: 10.1517/14740338.2014.884068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 103 |
Ferreirós N, Labocha S, El-duweik J, Schlecker C, Lötsch J, Geisslinger G. Quantitation of ribavirin in human plasma and red blood cells using LC-MS/MS: Liquid Chromatography. J Sep Science 2014;37:476-83. [DOI: 10.1002/jssc.201301173] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 104 |
Vogel W. Peginterferon-α 2a (40 kDa)/ribavirin combination for the treatment of chronic hepatitis C infection. Expert Review of Anti-infective Therapy 2014;1:423-31. [DOI: 10.1586/14787210.1.3.423] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 105 |
Bichoupan K, Schwartz JM, Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H, Dieterich DT, Branch AD, Reinus JF. Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther 2014;39:209-16. [PMID: 24266536 DOI: 10.1111/apt.12560] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 106 |
Agnesod D, De Nicolò A, Simiele M, Mohamed Abdi A, Boglione L, Di Perri G, D'Avolio A. Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients. J Pharm Biomed Anal 2014;90:119-26. [PMID: 24366212 DOI: 10.1016/j.jpba.2013.11.027] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 107 |
Clark PJ, Aghemo A, Degasperi E, Galmozzi E, Urban TJ, Vock DM, Patel K, Thompson AJ, Rumi MG, D'Ambrosio R, Muir AJ, Colombo M. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. J Viral Hepat 2013;20:858-66. [PMID: 24304455 DOI: 10.1111/jvh.12113] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 108 |
Oswald G, Alzoubi K, Abed M, Lang F. Stimulation of suicidal erythrocyte death by ribavirin. Basic Clin Pharmacol Toxicol 2014;114:311-7. [PMID: 24164926 DOI: 10.1111/bcpt.12165] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 109 |
Pol S. HCV, ribavirin, and anemia: a new dawn. Gastroenterology 2013;145:930-3. [PMID: 24060434 DOI: 10.1053/j.gastro.2013.09.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 110 |
Scherzer TM, Stättermayer AF, Stauber R, Maieron A, Strasser M, Laferl H, Schwarzer R, Datz C, Rutter K, Beinhardt S, Steindl-Munda P, Hofer H, Ferenci P. Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients. J Hepatol 2013;59:964-71. [PMID: 23850877 DOI: 10.1016/j.jhep.2013.06.030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 111 |
Wohl BM, Smith AA, Kryger MB, Zelikin AN. Narrow therapeutic window of ribavirin as an inhibitor of nitric oxide synthesis is broadened by macromolecular prodrugs. Biomacromolecules 2013;14:3916-26. [PMID: 24156371 DOI: 10.1021/bm401048s] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 112 |
D’avolio A, De Nicolò A, Cusato J, Ciancio A, Boglione L, Strona S, Cariti G, Troshina G, Caviglia GP, Smedile A, Rizzetto M, Di Perri G. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. Antiviral Research 2013;100:114-9. [DOI: 10.1016/j.antiviral.2013.07.021] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 113 |
Kawaguchi-suzuki M, Frye RF. The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection. Pharmacotherapy 2014;34:185-201. [DOI: 10.1002/phar.1349] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 114 |
Kryger MB, Smith AA, Wohl BM, Zelikin AN. Macromolecular prodrugs for controlled delivery of ribavirin. Macromol Biosci 2014;14:173-85. [PMID: 24105953 DOI: 10.1002/mabi.201300244] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 115 |
Lashin AH, Shaheen YA, Metwally MA, El-Feky HM, Hegab MF, Abbas SM. Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin. Indian J Gastroenterol 2013;32:316-23. [PMID: 23715642 DOI: 10.1007/s12664-013-0336-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 116 |
Aljofan M. Hendra and Nipah infection: emerging paramyxoviruses. Virus Res 2013;177:119-26. [PMID: 23954578 DOI: 10.1016/j.virusres.2013.08.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 117 |
Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y, Nishiura A, Kohjima M, Yoshimoto T, Fukuizumi K, Nakashima M, Kato M, Kotoh K, Nakamuta M, Enjoji M. Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy. World J Gastrointest Pharmacol Ther 2013; 4(3): 54-60 [PMID: 23919217 DOI: 10.4292/wjgpt.v4.i3.54] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 118 |
Kim JS, Ahn SM, Jung YK, Kwon OS, Kim YS, Choi DJ, Kim JH. The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean. J Korean Med Sci 2013;28:1213-9. [PMID: 23960450 DOI: 10.3346/jkms.2013.28.8.1213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 119 |
Lehners N, Schnitzler P, Geis S, Puthenparambil J, Benz MA, Alber B, Luft T, Dreger P, Eisenbach C, Kunz C, Benner A, Buchholz U, Aichinger E, Frank U, Heeg K, Ho AD, Egerer G. Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit. Bone Marrow Transplant 2013;48:1548-53. [DOI: 10.1038/bmt.2013.94] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 120 |
Feng Yeh C, Wang KC, Chiang LC, Shieh DE, Yen MH, San Chang J. Water extract of licorice had anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines. J Ethnopharmacol 2013;148:466-73. [PMID: 23643542 DOI: 10.1016/j.jep.2013.04.040] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 121 |
Dong SD, Lin CC, Schroeder M. Synthesis and evaluation of a new phosphorylated ribavirin prodrug. Antiviral Res 2013;99:18-26. [PMID: 23624267 DOI: 10.1016/j.antiviral.2013.04.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 122 |
Borroni G, Cazzaniga M, Andreoletti M, Ceriani R, Guerzoni P, Omazzi B, Pich MG, Prada A, Spinzi G, Terreni N, Salerno F. Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C. J Viral Hepat 2013;20:e90-5. [PMID: 23490395 DOI: 10.1111/jvh.12015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 123 |
Rau M, Stickel F, Russmann S, Manser CN, Becker PP, Weisskopf M, Schmitt J, Dill MT, Dufour JF, Moradpour D, Semela D, Müllhaupt B, Geier A; Swiss Hepatitis C Cohort Study Group (SCCS). Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. J Hepatol 2013;58:669-75. [PMID: 23195617 DOI: 10.1016/j.jhep.2012.11.027] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 124 |
Ahmed WH, Furusyo N, Zaky S, Sharaf Eldin A, Aboalam H, Ogawa E, Murata M, Hayashi J. Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients. World J Gastroenterol 2013; 19(9): 1387-1395 [PMID: 23538996 DOI: 10.3748/wjg.v19.i9.1387] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 125 |
Gara N, Ghany MG. What the infectious disease physician needs to know about pegylated interferon and ribavirin. Clin Infect Dis 2013;56:1629-36. [PMID: 23429551 DOI: 10.1093/cid/cit074] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 126 |
Xie XH, Zang N, Li SM, Wang LJ, Deng Y, He Y, Yang XQ, Liu EM. Resveratrol Inhibits respiratory syncytial virus-induced IL-6 production, decreases viral replication, and downregulates TRIF expression in airway epithelial cells. Inflammation. 2012;35:1392-1401. [PMID: 22391746 DOI: 10.1007/s10753-012-9452-7] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 127 |
Perng GC, Solbrig MV. Viral Hemorrhagic Fevers. Viral Infections of the Human Nervous System 2013. [DOI: 10.1007/978-3-0348-0425-7_14] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 128 |
Okano M, Okuse C, Yotsuyanagi H, Shima J, Hattori N, Shigefuku R, Noguchi Y, Hatsugai M, Nakahara K, Ikeda H, Takahashi H, Matsunaga K, Matsumoto N, Ishii T, Sato A, Fukuda Y, Koike K, Suzuki M, Itoh F. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C associated with thyroid dysfunction. Kanzo 2013;54:731-740. [DOI: 10.2957/kanzo.54.731] [Reference Citation Analysis]
|
| 129 |
Karasawa T, Saito T, Ueno Y, Sugimoto M, Soga T. Metabolome analysis of erythrocytes from patients with chronic hepatitis C reveals the etiology of ribavirin-induced hemolysis. Int J Med Sci 2013;10:1575-7. [PMID: 24046534 DOI: 10.7150/ijms.6436] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 130 |
Tsubota A, Shimada N, Abe H, Yoshizawa K, Agata R, Yumoto Y, Ika M, Namiki Y, Nagatsuma K, Matsudaira H, Fujise K, Tada N, Aizawa Y. Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C. World J Gastroenterol 2012; 18(41): 5879-5888 [PMID: 23139603 DOI: 10.3748/wjg.v18.i41.5879] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 131 |
Kobayashi T, Hige S, Terashita K, Nakai M, Horimoto H, Sho T, Nakanishi M, Ogawa K, Chuma M, Sakamoto N, Asaka M. Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C. J Gastroenterol 2012;47:1228-37. [PMID: 22460221 DOI: 10.1007/s00535-012-0579-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 132 |
Osinusi A, Naggie S, Poonia S, Trippler M, Hu Z, Funk E, Schlaak J, Fishbein D, Masur H, Polis M. ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. J Med Virol. 2012;84:1106-1114. [PMID: 22585729 DOI: 10.1002/jmv.23302] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 133 |
Tseng CW, Hsieh YH, Chang CK, Lai NS, Hung TH, Wu SF, Tseng KC. HLA-B*15:02 is associated with anemia in patients with chronic hepatitis C treated with pegylated interferon-α and ribavirin. Tissue Antigens 2012;80:424-30. [PMID: 22931407 DOI: 10.1111/j.1399-0039.2012.01956.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 134 |
Kleinegris MC, Koek GH, Mast K, Mestrom EH, Wolfs JL, Bevers EM. Ribavirin-induced externalization of phosphatidylserine in erythrocytes is predominantly caused by inhibition of aminophospholipid translocase activity. Eur J Pharmacol 2012;693:1-6. [PMID: 22959357 DOI: 10.1016/j.ejphar.2012.07.041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 135 |
Eskesen AN, Melum E, Moghaddam A, Bjøro K, Verbaan H, Ring-Larsen H, Dalgard O. Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. Eur J Gastroenterol Hepatol 2012;24:890-6. [PMID: 22584257 DOI: 10.1097/MEG.0b013e3283546efd] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 136 |
Palmer M, Rubin R, Rustgi V; Taribavirin Viral Kinetic Study Group. Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1. Aliment Pharmacol Ther 2012;36:370-8. [PMID: 22708649 DOI: 10.1111/j.1365-2036.2012.05188.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 137 |
Suzuki M, Inage E, Minowa K, Saito N, Naritaka N, Tsubahara M, Ohtsuka Y, Tokita A, Shimizu T. Prophylaxis for ribavirin-related anemia using eicosapentaenoic acid in chronic hepatitis C patients. Pediatr Int 2012;54:528-31. [PMID: 22375604 DOI: 10.1111/j.1442-200X.2012.03603.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 138 |
Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, Rosenthal P, Schwarz KB; North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012;54:838-55. [PMID: 22487950 DOI: 10.1097/MPG.0b013e318258328d] [Cited by in Crossref: 151] [Cited by in F6Publishing: 143] [Article Influence: 13.7] [Reference Citation Analysis]
|
| 139 |
Ding X, Sanchez DJ, Shahangian A, Al-Shyoukh I, Cheng G, Ho CM. Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity. Int J Nanomedicine 2012;7:2281-92. [PMID: 22654513 DOI: 10.2147/IJN.S27540] [Cited by in Crossref: 7] [Cited by in F6Publishing: 27] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 140 |
D'avolio A, Ciancio A, Siccardi M, Smedile A, Baietto L, Simiele M, Marucco DA, Cariti G, Calcagno A, de Requena DG, Sciandra M, Cusato J, Troshina G, Bonora S, Rizzetto M, Di Perri G. Inosine Triphosphatase Polymorphisms and Ribavirin Pharmacokinetics as Determinants of Ribavirin-Associate Anemia in Patients Receiving Standard Anti-HCV Treatment. Therapeutic Drug Monitoring 2012;34:165-70. [DOI: 10.1097/ftd.0b013e31824bf778] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 141 |
Perrakis A, Yedibela S, Schuhmann S, Croner R, Schellerer V, Demir R, Hohenberger W, Müller V. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin. Transplant Proc. 2011;43:3824-3828. [PMID: 22172854 DOI: 10.1016/j.transproceed.2011.08.103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 142 |
D'Avolio A, De Nicolò A, Simiele M, Turini S, Agnesod D, Boglione L, Cusato J, Baietto L, Cariti G, Calcagno A, Sciandra M, Di Perri G, Bonora S. Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. J Pharm Biomed Anal 2012;66:376-80. [PMID: 22513116 DOI: 10.1016/j.jpba.2012.03.030] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 143 |
Domingo P, Guardiola JM, Salazar J, Torres F, Mateo MG, Pacho C, Del Mar Gutierrez M, Lamarca K, Fontanet A, Martin J. Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy. Antimicrob Agents Chemother. 2012;56:2987-2993. [PMID: 22430973 DOI: 10.1128/aac.06473-11] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 144 |
Lee LY, Tong CY, Wong T, Wilkinson M. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials: Hepatitis looks set to be a curable illness. International Journal of Clinical Practice 2012;66:342-55. [DOI: 10.1111/j.1742-1241.2012.02895.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 145 |
Schlecker C, Ultsch A, Geisslinger G, Lötsch J. The pharmacogenetic background of hepatitis C treatment. Mutat Res. 2012;Epub ahead of print. [PMID: 22409946 DOI: 10.1016/j.mrrev.2012.02.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 146 |
Naik GS, Tyagi MG. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection. J Clin Exp Hepatol 2012;2:42-54. [PMID: 25755405 DOI: 10.1016/S0973-6883(12)60090-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 147 |
Wadhawan M, Taneja S, Shandil R, Goyal N, Gupta S, Kumar A. Management of chronic hepatitis C before and after liver transplant. Apollo Medicine 2012;9:24-31. [DOI: 10.1016/s0976-0016(12)60116-1] [Reference Citation Analysis]
|
| 148 |
Stickel F, Helbling B, Heim M, Geier A, Hirschi C, Terziroli B, Wehr K, De Gottardi A, Negro F, Gerlach T. Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. J Viral Hepat 2012;19:77-87. [PMID: 22239497 DOI: 10.1111/j.1365-2893.2011.01527.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 149 |
Choi J. Oxidative stress, endogenous antioxidants, alcohol, and hepatitis C: pathogenic interactions and therapeutic considerations. Free Radic Biol Med. 2012;52:1135-1150. [PMID: 22306508 DOI: 10.1016/j.freeradbiomed.2012.01.008] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 150 |
Simón-Talero M, Buti M, Esteban R. Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction? J Viral Hepat 2012;19 Suppl 1:14-7. [PMID: 22233409 DOI: 10.1111/j.1365-2893.2011.01521.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 151 |
Tillmann HL, Mchutchison JG. Hepatitis C. Zakim and Boyer's Hepatology 2012. [DOI: 10.1016/b978-1-4377-0881-3.00031-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 152 |
Gane EJ. Treating Chronic HCV Without Interferon and/or Ribavirin. Chronic Hepatitis C Virus 2012. [DOI: 10.1007/978-1-4614-1192-5_20] [Reference Citation Analysis]
|
| 153 |
Assem M, Yousri M. Impact of Pentoxifylline and Vitamin E on Ribavirin-induced Hemolytic Anemia in Chronic Hepatitis C Patients: An Egyptian Survey. Euroasian Journal of Hepato-Gastroenterology 2012;2:35-40. [DOI: 10.5005/jp-journals-10018-1029] [Reference Citation Analysis]
|
| 154 |
Chung R, Ketwaroo GA. Hepatitis C Virus Treatment in HIV. HIV and Liver Disease 2012. [DOI: 10.1007/978-1-4419-1712-6_15] [Reference Citation Analysis]
|
| 155 |
Darling JM, Lemon SM, Fried MW. Hepatitis C. Schiff's Diseases of the Liver 2011. [DOI: 10.1002/9781119950509.ch25] [Reference Citation Analysis]
|
| 156 |
Naggie S, Rallon NI, Benito JM, Morello J, Rodriguez-Novoa S, Clark PJ, Thompson AJ, Shianna KV, Vispo E, McHutchison JG. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. J Infect Dis. 2012;205:376-383. [PMID: 22158703 DOI: 10.1093/infdis/jir754] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 157 |
Lötsch J, Hofmann WP, Schlecker C, Zeuzem S, Geisslinger G, Ultsch A, Doehring A. Single and combined IL28B , ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy. Pharmacogenomics 2011;12:1729-40. [DOI: 10.2217/pgs.11.99] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 158 |
Shiffman ML. Cytopenias: How they Limit Therapy and Potential Correction. Advanced Therapy for Hepatitis C 2011. [DOI: 10.1002/9781444346343.ch20] [Reference Citation Analysis]
|
| 159 |
Gane E. Treatment of Recurrent Hepatitis C Following Liver Transplantation. Advanced Therapy for Hepatitis C 2011. [DOI: 10.1002/9781444346343.ch18] [Reference Citation Analysis]
|
| 160 |
Loustaud-Ratti V, Carrier P, Rousseau A, Maynard M, Babany G, Alain S, Trépo C, De Ledinghen V, Bourlière M, Pol S, Di Martino V, Zarski JP, Pinta A, Sautereau D, Marquet P; OPTIRIB group. Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment. Dig Liver Dis 2011;43:850-5. [PMID: 21596633 DOI: 10.1016/j.dld.2011.04.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 161 |
Bunchorntavakul C, Reddy KR. Ribavirin: How Does it Work and is it Still Needed? Curr Hepatitis Rep 2011;10:168-78. [DOI: 10.1007/s11901-011-0102-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 162 |
Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Nakamura Y, Kamatani N, Chayama K. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. J Med Virol 2011;83:1048-57. [PMID: 21503919 DOI: 10.1002/jmv.22069] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 163 |
Cariani E, Villa E, Rota C, Critelli R, Trenti T. Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection. Clin Chem Lab Med. 2011;49:1247-1256. [PMID: 21612542 DOI: 10.1515/cclm.2011.618] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 164 |
Mistry PK, Jain D. Haematological Disorders of the Liver. Sherlock's Diseases of the Liver and Biliary System 2011. [DOI: 10.1002/9781444341294.ch4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 165 |
Chang CS, Yan SL, Lin HY, Yu FL, Tsai CY. Pure red cell aplasia caused by pegylated interferon-α-2a plus ribavirin in the treatment of chronic hepatitis C. World J Gastroenterol 2011; 17(16): 2155-2158 [PMID: 21547138 DOI: 10.3748/wjg.v17.i16.2155] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 166 |
Carrion AF, Fabrizi F, Martin P. Should ribavirin be used to treat hepatitis C in dialysis patients? Semin Dial. 2011;24:272-274. [PMID: 21480995 DOI: 10.1111/j.1525-139x.2011.00851.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 167 |
Hitomi Y, Cirulli ET, Fellay J, McHutchison JG, Thompson AJ, Gumbs CE, Shianna KV, Urban TJ, Goldstein DB. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 2011;140:1314-21. [PMID: 21199653 DOI: 10.1053/j.gastro.2010.12.038] [Cited by in Crossref: 100] [Cited by in F6Publishing: 104] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 168 |
Calvaruso V, Mazza M, Almasio PL. Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects. Expert Opin Drug Saf 2011;10:429-35. [PMID: 21323500 DOI: 10.1517/14740338.2011.559161] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 169 |
Krishnan SM, Dixit NM. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. PLoS Comput Biol 2011;7:e1001072. [PMID: 21304937 DOI: 10.1371/journal.pcbi.1001072] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 170 |
Merwat SN, Vierling JM. HIV infection and the liver: the importance of HCV-HIV coinfection and drug-induced liver injury. Clin Liver Dis 2011;15:131-52. [PMID: 21111997 DOI: 10.1016/j.cld.2010.09.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 171 |
Suzuki F, Suzuki Y, Akuta N, Sezaki H, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Chayama K, Kamatani N, Nakamura Y, Miyakawa Y, Kumada H. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011;53:415-21. [PMID: 21246582 DOI: 10.1002/hep.24058] [Cited by in Crossref: 83] [Cited by in F6Publishing: 87] [Article Influence: 6.9] [Reference Citation Analysis]
|
| 172 |
Farrell CP, Mercogliano G, Navarro VJ, Rossi S. Taribavirin: potential future in the treatment of hepatitis C. Future Virology 2011;6:147-55. [DOI: 10.2217/fvl.10.81] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 173 |
Assem M, Yousri M. Impact of pentoxifylline and vitamin e on ribavirin-induced haemolytic anaemia in chronic hepatitis C patients: an egyptian survey. Int J Hepatol 2011;2011:530949. [PMID: 21994862 DOI: 10.4061/2011/530949] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 174 |
Sung H, Chang M, Saab S. Management of Hepatitis C Antiviral Therapy Adverse Effects. Curr Hepat Rep. 2011;10:33-40. [PMID: 21423320 DOI: 10.1007/s11901-010-0078-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 175 |
Kubota R, Komiyama T, Kumagai N, Kimijima M, Mitsuki K, Uetake J, Kaneko F, Tsunematsu S, Tsuchimoto K. Optimal erythrocyte ribavirin level to reduce the risk of anemia and obtain an early virological response in patients with chronic hepatitis C caused by genotype 1b infection. Hepat Res Treat 2010;2010:495928. [PMID: 21151503 DOI: 10.1155/2010/495928] [Reference Citation Analysis]
|
| 176 |
Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, Herrine SK, Harrison SA, Poordad FF, Koury K, Deng W, Noviello S, Pedicone LD, Brass CA, Albrecht JK, McHutchison JG; IDEAL Study Team. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010;139:1602-11, 1611.e1. [PMID: 20723545 DOI: 10.1053/j.gastro.2010.07.059] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 6.9] [Reference Citation Analysis]
|
| 177 |
Pendse A, Fedoriw Y, Willis MS. Unexpected Cause of Anemia in a 45-Year-Old Patient With Acute Lymphoblastic Leukemia. Lab Med 2010;41:645-8. [DOI: 10.1309/lmk7oa1gyp3srdbd] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 178 |
Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, Tsunoda T, Hayes CN, Kumada H, Nakamura Y, Chayama K. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. Gastroenterology 2010;139:1190-7. [PMID: 20637204 DOI: 10.1053/j.gastro.2010.06.071] [Cited by in Crossref: 140] [Cited by in F6Publishing: 148] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 179 |
Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, Urban TJ, Shianna KV, Muir AJ, Fried MW, Afdhal NH, Goldstein DB, McHutchison JG. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010;139:1181-9. [PMID: 20547162 DOI: 10.1053/j.gastro.2010.06.016] [Cited by in Crossref: 149] [Cited by in F6Publishing: 161] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 180 |
Poordad F, Lawitz E, Shiffman ML, Hassanein T, Muir AJ, Bacon BR, Heise J, Halliman D, Chun E, Hammond J. Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Hepatology 2010;52:1208-15. [PMID: 20721883 DOI: 10.1002/hep.23827] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 181 |
Jonathan B, Christoph Z, Jeremy L, Michael F. Recent Advances in Hepatitis C Therapies. Burger's Medicinal Chemistry and Drug Discovery 2010. [DOI: 10.1002/0471266949.bmc238] [Reference Citation Analysis]
|
| 182 |
Basseri RJ, Schmidt MT, Basseri B. Autoimmune hemolytic anemia in treatment-naive chronic hepatitis C infection: a case report and review of literature. Clin J Gastroenterol 2010;3:237-42. [DOI: 10.1007/s12328-010-0165-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 183 |
Singethan K, Hiltensperger G, Kendl S, Wohlfahrt J, Plattet P, Holzgrabe U, Schneider-Schaulies J. N-(3-Cyanophenyl)-2-phenylacetamide, an effective inhibitor of morbillivirus-induced membrane fusion with low cytotoxicity. J Gen Virol 2010;91:2762-72. [PMID: 20685931 DOI: 10.1099/vir.0.025650-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 184 |
Bertino G, Ardiri A, Boemi PM, Calvagno GS, Ruggeri IM, Speranza A, Santonocito MM, Ierna D, Bruno CM, Valenti M. Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis. Eur J Clin Pharmacol. 2010;66:1055-1063. [PMID: 20652232 DOI: 10.1007/s00228-010-0868-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 185 |
Negro F. Adverse effects of drugs in the treatment of viral hepatitis. Best Pract Res Clin Gastroenterol 2010;24:183-92. [PMID: 20227031 DOI: 10.1016/j.bpg.2009.10.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 186 |
Vispo E, Labarga P, Guardiola JM, Barreiro P, Miralles C, Rubio R, Miralles P, Aguirrebengoa K, Portu J, Morello J, Rodriguez-Novoa S, Soriano V; PERICO Study Group. Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C. AIDS Res Hum Retroviruses 2010;26:419-24. [PMID: 20377423 DOI: 10.1089/aid.2009.0120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 187 |
Sood A, Sobti P, Midha V, Singla D, Kaur A, Kaushal S, Sood N, Mittal R, Puri S. Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C. Indian J Gastroenterol 2010;29:62-5. [PMID: 20443101 DOI: 10.1007/s12664-010-0014-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 188 |
Tiu C, Nasika S, Desani J, Rose M, Ghitan M. Nafcillin Induced Hemolytic Anemia with Negative Coombs Test Results. Infectious Diseases in Clinical Practice 2010;18:146-147. [DOI: 10.1097/ipc.0b013e3181c5eef7] [Reference Citation Analysis]
|
| 189 |
Falasca K, Ucciferri C, Mancino P, Gorgoretti V, Pizzigallo E, Vecchiet J. Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response. J Med Virol 2010;82:49-56. [PMID: 19950239 DOI: 10.1002/jmv.21657] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 190 |
Brok J, Gluud LL, Gluud C; Cochrane Hepato-Biliary Group. Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd005445.pub2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 191 |
ANTIVIRAL DRUGS, INCLUDING IMMUNOGLOBULINS AND INTERFERONS. Meyler's Side Effects of Antimicrobial Drugs 2010. [DOI: 10.1016/b978-0-444-53272-5.50006-6] [Reference Citation Analysis]
|
| 192 |
Chan AH, Partovi N, Ensom MH. The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review. Ann Pharmacother 2009;43:2044-63. [PMID: 19920162 DOI: 10.1345/aph.1M225] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 193 |
Aljofan M, Sganga ML, Lo MK, Rootes CL, Porotto M, Meyer AG, Saubern S, Moscona A, Mungall BA. Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro. Virol J 2009;6:187. [PMID: 19889218 DOI: 10.1186/1743-422X-6-187] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 194 |
Brok J, Gluud LL, Gluud C. Ribavirin monotherapy for chronic hepatitis C. Cochrane Database Syst Rev. 2009;CD005527. [PMID: 19821346 DOI: 10.1002/14651858.cd005527.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 195 |
Kawaguchi Y, Mizuta T. Supplementation With High Doses Of Vitamins E And C In Chronic Hepatitis C. Nutrition, Diet Therapy, and the Liver 2009. [DOI: 10.1201/9781420085501.ch17] [Reference Citation Analysis]
|
| 196 |
Dahari H, Shudo E, Ribeiro RM, Perelson AS. Mathematical modeling of HCV infection and treatment. Methods Mol Biol 2009;510:439-53. [PMID: 19009281 DOI: 10.1007/978-1-59745-394-3_33] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 197 |
Shields WW, Pockros PJ. Ribavirin analogs. Clin Liver Dis 2009;13:419-27. [PMID: 19628158 DOI: 10.1016/j.cld.2009.05.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 198 |
Ancel D, Amiot X, Chaslin-Ferbus D, Hagege I, Garioud A, Girot R, Pol S, Grange JD. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin. Eur J Gastroenterol Hepatol 2009;21:726-9. [PMID: 19404206 DOI: 10.1097/MEG.0b013e3283097699] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 199 |
Iacobellis A, Andriulli A. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection. Expert Opinion on Pharmacotherapy 2009;10:1929-38. [DOI: 10.1517/14656560903066811] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 200 |
Loustaud-Ratti V, Rousseau A, Marquet P, Denis F, Alain S. Ribavirin in chronic hepatitis C: past and future. Expert Rev Anti Infect Ther. 2009;7:249-253. [PMID: 19344238 DOI: 10.1586/eri.09.5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 201 |
Takeshita M, Ishida Y, Akamatsu E, Ohmori Y, Sudoh M, Uto H, Tsubouchi H, Kataoka H. Proanthocyanidin from blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA. J Biol Chem. 2009;284:21165-21176. [PMID: 19531480 DOI: 10.1074/jbc.m109.004945] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 202 |
Tseng KC, Chen LH, Chen CY, Chang TT, Chou AL, Wu IC, Cheng PN. Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b. Hepatol Res 2009;39:539-45. [PMID: 19254345 DOI: 10.1111/j.1872-034X.2009.00489.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 203 |
Nelson DR, Davis GL, Jacobson I, Everson GT, Fried MW, Harrison SA, Hassanein T, Jensen DM, Lindsay KL, Terrault N, Zein N. Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol 2009;7:397-414; quiz 366. [PMID: 19114127 DOI: 10.1016/j.cgh.2008.11.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 204 |
Reddy KR, Nelson DR, Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol 2009;50:402-11. [PMID: 19091439 DOI: 10.1016/j.jhep.2008.11.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 205 |
Aljofan M, Saubern S, Meyer AG, Marsh G, Meers J, Mungall BA. Characteristics of Nipah virus and Hendra virus replication in different cell lines and their suitability for antiviral screening. Virus Res 2009;142:92-9. [PMID: 19428741 DOI: 10.1016/j.virusres.2009.01.014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 206 |
Endres CJ, Moss AM, Ke B, Govindarajan R, Choi DS, Messing RO, Unadkat JD. The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. J Pharmacol Exp Ther. 2009;329:387-398. [PMID: 19164463 DOI: 10.1124/jpet.108.145854] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 207 |
Kiser JJ. Trends in the Treatment of Chronic Hepatitis C Virus Infection. Journal of Pharmacy Practice 2009;22:405-18. [DOI: 10.1177/0897190008328695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 208 |
Shiffman ML. What future for ribavirin? Liver Int 2009;29 Suppl 1:68-73. [PMID: 19207968 DOI: 10.1111/j.1478-3231.2008.01936.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 209 |
Fox AN, Faust TW. Support of Patients During Antiviral Therapy for Hepatitis B and C. Chronic Viral Hepatitis 2009. [DOI: 10.1007/978-1-59745-565-7_13] [Reference Citation Analysis]
|
| 210 |
Rodríguez-Nóvoa S, Morello J, González M, Vispo E, Barreiro P, González-Pardo G, Jiménez-Nácher I, Gonzalez-Lahoz J, Soriano V. Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. AIDS 2008;22:2535-7. [PMID: 19005277 DOI: 10.1097/QAD.0b013e3283177f38] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 211 |
Azim J, McCurdy H, Moseley RH. Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C. World J Gastroenterol 2008; 14(38): 5913-5915 [PMID: 18855993 DOI: 10.3748/wjg.14.5913] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 212 |
Mungall BA, Schopman NC, Lambeth LS, Doran TJ. Inhibition of Henipavirus infection by RNA interference. Antiviral Res 2008;80:324-31. [PMID: 18687361 DOI: 10.1016/j.antiviral.2008.07.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 213 |
Lo Re V 3rd, Kostman JR, Amorosa VK. Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis 2008;12:587-609, ix. [PMID: 18625430 DOI: 10.1016/j.cld.2008.03.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 214 |
Shiffman ML. Optimizing the current therapy for chronic hepatitis C virus: peginterferon and ribavirin dosing and the utility of growth factors. Clin Liver Dis 2008;12:487-505, vii. [PMID: 18625425 DOI: 10.1016/j.cld.2008.03.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 215 |
Turbide C, Soulellis C, Deschênes M, Hilzenrat N. Does a rapid decline in the hematological and biochemical parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustained viral response? Can J Gastroenterol 2008;22:149-52. [PMID: 18299740 DOI: 10.1155/2008/213897] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 216 |
Martin P, Jensen DM. Ribavirin in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 2008;23:844-55. [PMID: 18565019 DOI: 10.1111/j.1440-1746.2008.05398.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 217 |
Bourliere M. Traitement de l’hépatite C : gestion des effets secondaires. Gastroentérologie Clinique et Biologique 2008;32:S166-71. [DOI: 10.1016/j.gcb.2008.04.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 218 |
Chung DH, Kumarapperuma SC, Sun Y, Li Q, Chu YK, Arterburn JB, Parker WB, Smith J, Spik K, Ramanathan HN, Schmaljohn CS, Jonsson CB. Synthesis of 1-beta-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus. Antiviral Res 2008;79:19-27. [PMID: 18394724 DOI: 10.1016/j.antiviral.2008.02.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 219 |
Kawashima A, Tsukamoto I, Koyabu T, Murakami Y, Kawakami T, Kakibuchi N, Takaguchi K, Kita K, Okita M. Eicosapentaenoic Acid Supplementation for Chronic Hepatitis C Patients During Combination Therapy of Pegylated Interferon α-2b and Ribavirin. Lipids 2008;43:325-33. [DOI: 10.1007/s11745-008-3157-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 220 |
Aljofan M, Porotto M, Moscona A, Mungall BA. Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus. J Virol Methods 2008;149:12-9. [PMID: 18313148 DOI: 10.1016/j.jviromet.2008.01.016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 221 |
Sethi A, Shiffman ML. Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response. Infect Dis Clin North Am. 2006;20:115-135. [PMID: 16527652 DOI: 10.1016/j.idc.2006.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 222 |
Takaki S, Kawakami Y, Imamura M, Aikata H, Takahashi S, Ishihara H, Tsuji K, Aimitsu S, Kawakami H, Nakanishi T, Kitamoto M, Moriya T, Satoh K, Chayama K. Eicosapentaenoic Acid Could Permit Maintenance of the Original Ribavirin Dose in Chronic Hepatitis C Virus Patients during the First 12 Weeks of Combination Therapy with Pegylated Interferon-α and Ribavirin. Intervirology 2008;50:439-46. [DOI: 10.1159/000114718] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 223 |
Hiramatsu N, Kurashige N, Oze T, Takehara T, Tamura S, Kasahara A, Oshita M, Katayama K, Yoshihara H, Imai Y, Kato M, Kawata S, Tsubouchi H, Kumada H, Okanoue T, Kakumu S, Hayashi N. Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C. Hepatol Res 2008;38:52-9. [PMID: 17714473 DOI: 10.1111/j.1872-034X.2007.00205.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 224 |
Kubota R, Kumagai N, Komiyama T, Kimijima M, Kaneko F, Tsunematsu S, Tsuchimoto K. Osmotic fragility of erythrocyte for the prediction of Ribavirin induced anemia in patients with chronic hepatitis C viral infection. Kanzo 2008;49:6-13. [DOI: 10.2957/kanzo.49.6] [Reference Citation Analysis]
|
| 225 |
Matthews SJ, Mccoy C. Pegylated Interferons: Clinical Applications in the Management of Hepatitis C Infection. Hepatitis C Virus Disease 2008. [DOI: 10.1007/978-0-387-71376-2_12] [Reference Citation Analysis]
|
| 226 |
Dusheiko G, Nelson D, Reddy KR. Ribavirin considerations in treatment optimization. Antiviral Therapy 2008;13:23-30. [DOI: 10.1177/135965350801301s02] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 227 |
Mira JA, López-cortés LF, Merino D, Arizcorreta-yarza A, Rivero A, Collado A, Ríos-villegas MJ, González-serrano M, Torres-tortosa M, Macías J, Valera-bestard B, Fernández-fuertes E, Girón-gonzález JA, Lozano F, Pineda JA; for the Grupo para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Predictors of Severe Haematological Toxicity Secondary to Pegylated Interferon plus Ribavirin Treatment in HIV-HCV-Coinfected Patients. Antiviral Therapy 2007;12:1225-36. [DOI: 10.1177/135965350701200805] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 228 |
Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev. 2007;CD003620. [PMID: 17943794 DOI: 10.1002/14651858.cd003620.pub3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 32] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 229 |
Cacoub P, Piroth L. Prise en charge des malades coinfectés VIH-VHC et VIH-VHB. Gastroentérologie Clinique et Biologique 2007;31:887-94. [DOI: 10.1016/s0399-8320(07)73986-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 230 |
Pol S, Cacoub P, Pialoux G, Benhamou Y, Halfon P, Rosenthal E, Perronne C. Prise en charge des patients co-infectés VIH-VHC. Gastroentérologie Clinique et Biologique 2007;31:7-12. [DOI: 10.1016/s0399-8320(07)92557-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 231 |
Larrey D, Couzigou P, Denis J. Hépatite chronique C : gestion des effets indésirables du traitement. Gastroentérologie Clinique et Biologique 2007;31:20-8. [DOI: 10.1016/s0399-8320(07)92559-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 232 |
Shiffman ML, Salvatore J, Hubbard S, Price A, Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007;46:371-9. [PMID: 17559152 DOI: 10.1002/hep.21712] [Cited by in Crossref: 158] [Cited by in F6Publishing: 163] [Article Influence: 9.9] [Reference Citation Analysis]
|
| 233 |
Halpin K, Mungall BA. Recent progress in henipavirus research. Comp Immunol Microbiol Infect Dis 2007;30:287-307. [PMID: 17629946 DOI: 10.1016/j.cimid.2007.05.008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 234 |
Dahari H, Markatou M, Zeremski M, Haller I, Ribeiro RM, Licholai T, Perelson AS, Talal AH. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007;47:23-30. [PMID: 17412448 DOI: 10.1016/j.jhep.2007.01.027] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 235 |
Benhamou Y. Anemia and clinical outcomes in hepatitis C. J Hepatol 2007;47:7-9. [PMID: 17509719 DOI: 10.1016/j.jhep.2007.04.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 236 |
Saab S, Oh MK, Ibrahim AB, Durazo F, Han S, Yersiz H, Farmer DG, Ghobrial RM, Goldstein LI, Tong MJ, Busuttil RW. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007;13:1032-8. [PMID: 17600345 DOI: 10.1002/lt.21184] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 237 |
Seronello S, Sheikh MY, Choi J. Redox regulation of hepatitis C in nonalcoholic and alcoholic liver. Free Radic Biol Med 2007;43:869-82. [PMID: 17697932 DOI: 10.1016/j.freeradbiomed.2007.05.036] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 238 |
Kawaguchi Y, Mizuta T, Takahashi K, Iwane S, Ario K, Kawasoe H, Hamaoka K, Eguchi Y, Yasutake T, Shigematsu H, Kawazoe S, Fukushima N, Ozaki I, Fujimoto K. High-dose vitamins E and C supplementation prevents ribavirin-induced hemolytic anemia in patients with chronic hepatitis C. Hepatol Res 2007;37:317-24. [PMID: 17441803 DOI: 10.1111/j.1872-034X.2007.00039.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 239 |
McHutchison JG, Manns MP, Brown RS Jr, Reddy KR, Shiffman ML, Wong JB. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007;102:880-9. [PMID: 17397412 DOI: 10.1111/j.1572-0241.2007.01139.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 240 |
Ciccaglione AR, Marcantonio C, Tritarelli E, Equestre M, Vendittelli F, Costantino A, Geraci A, Rapicetta M. Activation of the ER stress gene gadd153 by hepatitis C virus sensitizes cells to oxidant injury. Virus Res. 2007;126:128-138. [PMID: 17368854 DOI: 10.1016/j.virusres.2007.02.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 241 |
Kadam JS, Talal AH. Changing treatment paradigms: hepatitis C virus in HIV-infected patients. AIDS Patient Care STDS 2007;21:154-68. [PMID: 17428183 DOI: 10.1089/apc.2006.0126] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 242 |
Vilar Gomez E, Gra Oramas B, Soler E, Llanio Navarro R, Ruenes Domech C. Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Liver Int 2007;27:247-59. [PMID: 17311621 DOI: 10.1111/j.1478-3231.2006.01411.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 243 |
Yoshida EM, Dar Santos A, Partovi N, Ford JA. Erythropoietin and hepatitis C therapy: useful adjuvant therapy but remember to treat the patient and not just a number. Can J Gastroenterol 2006;20:519-20. [PMID: 16967572 DOI: 10.1155/2006/793589] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 244 |
Saito H, Tada S, Ebinuma H, Ishii H, Kashiwazaki K, Takahashi M, Tsukada N, Nishida J, Tanaka S, Shiozaki H, Hibi T. Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections. J Clin Microbiol 2006;44:3562-8. [PMID: 17021083 DOI: 10.1128/JCM.00079-06] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 245 |
Pol S, Bourlière M. Optimizing Treatment Outcomes in Chronic Hepatitis C: Management of Non-Response. Antiviral Therapy 2006;11:955-970. [DOI: 10.1177/135965350601100815] [Reference Citation Analysis]
|
| 246 |
Bardet V, Junior AP, Coste J, Lecoq-Lafon C, Chouzenoux S, Bernard D, Soubrane O, Lacombe C, Calmus Y, Conti F. Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors. Liver Transpl 2006;12:1649-54. [PMID: 17058250 DOI: 10.1002/lt.20898] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 247 |
Rossi R, Giustarini D, Milzani A, Dalle-Donne I. Membrane skeletal protein S-glutathionylation and hemolysis in human red blood cells. Blood Cells Mol Dis 2006;37:180-7. [PMID: 17059889 DOI: 10.1016/j.bcmd.2006.09.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 248 |
Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006;13:683-9. [PMID: 16970600 DOI: 10.1111/j.1365-2893.2006.00749.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 249 |
Andrade R. Manejo de los efectos adversos del tratamiento. Gastroenterología y Hepatología 2006;29:184-9. [DOI: 10.1157/13097657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 250 |
Mungall BA, Middleton D, Crameri G, Bingham J, Halpin K, Russell G, Green D, McEachern J, Pritchard LI, Eaton BT, Wang LF, Bossart KN, Broder CC. Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol 2006;80:12293-302. [PMID: 17005664 DOI: 10.1128/JVI.01619-06] [Cited by in Crossref: 120] [Cited by in F6Publishing: 126] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 251 |
Greenberg PD, Rosman AS, Eldeiry LS, Naqvi Z, Bräu N. Decline in haemoglobin A1c values in diabetic patients receiving interferon-alpha and ribavirin for chronic hepatitis C. J Viral Hepat 2006;13:613-7. [PMID: 16907848 DOI: 10.1111/j.1365-2893.2006.00729.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 252 |
Oze T, Hiramatsu N, Kurashige N, Tsuda N, Yakushijin T, Kanto T, Takehara T, Kasahara A, Kato M, Yoshihara H, Katayama K, Kubota S, Hijioka T, Ishibashi K, Oshita M, Hagiwara H, Haruna Y, Mita E, Tamura S, Hayashi N. Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. J Gastroenterol 2006;41:862-72. [PMID: 17048050 DOI: 10.1007/s00535-006-1858-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 253 |
Hino K, Murakami Y, Nagai A, Kitase A, Hara Y, Furutani T, Ren F, Yamaguchi Y, Yutoku K, Yamashita S, Okuda M, Okita M, Okita K. Alpha-tocopherol [corrected] and ascorbic acid attenuates the ribavirin [corrected] induced decrease of eicosapentaenoic acid in erythrocyte membrane in chronic hepatitis C patients. J Gastroenterol Hepatol 2006;21:1269-75. [PMID: 16872308 DOI: 10.1111/j.1440-1746.2006.04378.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 254 |
Murakami Y, Nagai A, Kawakami T, Hino K, Kitase A, Hara Y, Okuda M, Okita K, Okita M. Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon alpha-2b and ribavirin. Nutrition. 2006;22:114-122. [PMID: 16459223 DOI: 10.1016/j.nut.2005.05.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 255 |
Perronne C. Antiviral hepatitis and antiretroviral drug interactions. J Hepatol 2006;44:S119-25. [PMID: 16360231 DOI: 10.1016/j.jhep.2005.11.025] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 256 |
Pawlotsky J, Gish RG. Future Therapies for Hepatitis C. Antiviral Therapy 2006;11:397-408. [DOI: 10.1177/135965350601100415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 257 |
McHutchison JG, Manns MP, Longo DL. Definition and management of anemia in patients infected with hepatitis C virus. Liver Int 2006;26:389-98. [PMID: 16629641 DOI: 10.1111/j.1478-3231.2006.01228.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 258 |
Donnerer J, Grahovac M, Stelzl E, Kessler HH, Bankuti C, Stadlbauer V, Stauber RE. Ribavirin Levels and Haemoglobin Decline in Early Virological Responders and Non-Responders to Hepatitis C Virus Combination Therapy. Pharmacology 2006;76:136-40. [DOI: 10.1159/000090942] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 259 |
Thevenot T, Di Martino V, Lunel-fabiani F, Vanlemmens C, Becker M, Bronowicki J, Bresson-hadni S, Miguet J. Traitements complémentaires de l’hépatite chronique virale C. Gastroentérologie Clinique et Biologique 2006;30:197-214. [DOI: 10.1016/s0399-8320(06)73154-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 260 |
Arese P, Turrini F, Schwarzer E. Band 3/complement-mediated recognition and removal of normally senescent and pathological human erythrocytes. Cell Physiol Biochem 2005;16:133-46. [PMID: 16301814 DOI: 10.1159/000089839] [Cited by in Crossref: 189] [Cited by in F6Publishing: 200] [Article Influence: 11.1] [Reference Citation Analysis]
|
| 261 |
Ribavirin. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions 2006. [DOI: 10.1016/b0-44-451005-2/00774-9] [Reference Citation Analysis]
|
| 262 |
Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-64; quiz 214-7. [PMID: 16401486 DOI: 10.1053/j.gastro.2005.11.010] [Cited by in Crossref: 276] [Cited by in F6Publishing: 304] [Article Influence: 16.2] [Reference Citation Analysis]
|
| 263 |
Santos SA, Kontorinis N, Dieterich DT. Management of chronic Hepatitis C virus in patients with HIV. Curr Treat Options Gastro 2005;8:433-41. [DOI: 10.1007/s11938-005-0029-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 264 |
Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006;57:8-13. [PMID: 16293677 DOI: 10.1093/jac/dki405] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 265 |
Sulkowski MS. Management of the hematologic complications of hepatitis C therapy. Clin Liver Dis 2005;9:601-16, vi. [PMID: 16207566 DOI: 10.1016/j.cld.2005.07.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 266 |
Brok J, Gluud LL, Gluud C, Brok J. Ribavirin monotherapy for chronic hepatitis C. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd005527] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 267 |
Fuster D, Huertas JA, Gómez G, Solà R, García JG, Vilaró J, Pedrol E, Force L, Tor J, Sirera G, Videla S, Planas R, Clotet B, Tural C, Fuster D, Tor J, Sirera G, Videla S, Planas R, Clotet B, Tural C, Huertas JA, Gómez G, Solà R, García JG, Vilaró J, Pedrol E, Force L, Cervantes M, García I, Roget M; for the PEG-TOX Research Group. Baseline Factors associated with Haematological Toxicity that Leads to a Dosage Reduction of Pegylated Interferon-α2a and Ribavirin in HIV- and HCV-Coinfected Patients on HCV Antiviral Therapy. Antiviral Therapy 2005;10:841-7. [DOI: 10.1177/135965350501000710] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 268 |
Chiou HE, Liu CL, Buttrey MJ, Kuo HP, Liu HW, Kuo HT, Lu YT. Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers. Chest 2005;128:263-72. [PMID: 16002945 DOI: 10.1378/chest.128.1.263] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 269 |
Tod M, Farcy-Afif M, Stocco J, Boyer N, Bouton V, Sinègre M, Marcellin P. Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. Clin Pharmacokinet 2005;44:417-28. [PMID: 15828854 DOI: 10.2165/00003088-200544040-00006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 270 |
Yedibela S, Schuppan D, Müller V, Schellerer V, Tannapfel A, Hohenberger W, Meyer T. Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation. Liver Int 2005;25:717-22. [PMID: 15998420 DOI: 10.1111/j.1478-3231.2005.1065.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 271 |
Sethi A, Shiffman ML. Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response. Clin Liver Dis 2005;9:453-71, vii-viii. [PMID: 16023977 DOI: 10.1016/j.cld.2005.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 272 |
Wu JZ, Larson G, Walker H, Shim JH, Hong Z. Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother 2005;49:2164-71. [PMID: 15917509 DOI: 10.1128/AAC.49.6.2164-2171.2005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 273 |
Motoo Y, Mouri H, Ohtsubo K, Yamaguchi Y, Watanabe H, Sawabu N. Herbal medicine Ninjinyoeito ameliorates ribavirin-induced anemia in chronic hepatitis C: A randomized controlled trial. World J Gastroenterol 2005; 11(26): 4013-4017 [PMID: 15996025 DOI: 10.3748/wjg.v11.i26.4013] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 274 |
Schmid M, Kreil A, Jessner W, Homoncik M, Datz C, Gangl A, Ferenci P, Peck-Radosavljevic M. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut 2005;54:1014-20. [PMID: 15951552 DOI: 10.1136/gut.2004.057893] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 275 |
Rivkin AM, Chawla S. Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus. Pharmacotherapy 2005;25:862-75. [PMID: 15927905 DOI: 10.1592/phco.2005.25.6.862] [Reference Citation Analysis]
|
| 276 |
Stravitz RT, Chung H, Sterling RK, Luketic VA, Sanyal AJ, Price AS, Purrington A, Shiffman ML. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol 2005;100:1415-9. [PMID: 15929778 DOI: 10.1111/j.1572-0241.2005.41910.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 277 |
Mazzaro C, Zorat F, Caizzi M, Donada C, Di Gennaro G, Maso LD, Carniello G, Virgolini L, Tirelli U, Pozzato G. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005;42:632-8. [PMID: 15826710 DOI: 10.1016/j.jhep.2004.10.031] [Cited by in Crossref: 101] [Cited by in F6Publishing: 105] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 278 |
Brok J, Gluud LL, Gluud C, Brok J. Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd005445] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 279 |
Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev. 2005;CD003620. [PMID: 15846671 DOI: 10.1002/14651858.cd003620.pub2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 280 |
Adragna NC, Di Fulvio M, Lauf PK. Regulation of K-Cl cotransport: from function to genes. J Membr Biol 2004;201:109-37. [PMID: 15711773 DOI: 10.1007/s00232-004-0695-6] [Cited by in Crossref: 160] [Cited by in F6Publishing: 167] [Article Influence: 8.9] [Reference Citation Analysis]
|
| 281 |
Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 2005;39:S3-8. [PMID: 15597025 DOI: 10.1097/01.mcg.0000145494.76305.11] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 282 |
Ninomiya T, Yano Y, Hamano K, Kato H, Kato M, Seo Y, Kasuga M. Efficacy of eicosapentaenoic acid for ribavirin-related anemia and oxidative stress in patients with chronic hepatitis C. Kanzo 2005;46:716-717. [DOI: 10.2957/kanzo.46.716] [Reference Citation Analysis]
|
| 283 |
Toyota J, Karino Y, Akaike J, Ohmura T, Sato T, Yamazaki K, Kuwata Y, Iino S. Total clearance (CL/F) of ribavirin is the factor most influencing incidence of hemolytic anemia in interferon .ALPHA. plus ribavirin combination therapy. Kanzo 2005;46:107-118. [DOI: 10.2957/kanzo.46.107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 284 |
Inoue Y, Homma M, Matsuzaki Y, Shibata M, Matsumura T, Ito T, Mitamura K, Tanaka N, Kohda Y. Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood. Antimicrob Agents Chemother 2004;48:3813-6. [PMID: 15388439 DOI: 10.1128/AAC.48.10.3813-3816.2004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 285 |
Morisco F, Verde V, Fogliano V, Ritieni A, Marmo R, De Luise G, Tuccillo C, Caporaso N. Oxidative status in chronic hepatitis C: the influence of antiviral therapy and prognostic value of serum hydroperoxide assay. Free Radic Res 2004;38:573-80. [PMID: 15346648 DOI: 10.1080/10715760410001688357] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 286 |
Aspinall RJ, Pockros PJ. The management of side-effects during therapy for hepatitis C. Aliment Pharmacol Ther 2004;20:917-29. [PMID: 15521838 DOI: 10.1111/j.1365-2036.2004.02192.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 287 |
Trivedi HS, Trivedi M. Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C. J Clin Gastroenterol 2004;38:595-8. [PMID: 15232364 DOI: 10.1097/00004836-200408000-00011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 288 |
Lahousen T, Hegenbarth K, Ille R, Lipp RW, Krause R, Little RR, Schnedl WJ. Determination of glycated hemoglobin in patients with advanced liver disease. World J Gastroenterol 2004; 10(15): 2284-2286 [PMID: 15259084 DOI: 10.3748/wjg.v10.i15.2284] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 289 |
Morisco F, Vitaglione P, Carbone A, Stingo S, Scarpati S, Ascione A, Marmo R, Fogliano V, Caporaso N. Tomato-based functional food as interferon adjuvant in HCV eradication therapy. J Clin Gastroenterol 2004;38:S118-20. [PMID: 15220675 DOI: 10.1097/01.mcg.0000128935.48082.f9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 290 |
Qadri I, Iwahashi M, Capasso JM, Hopken MW, Flores S, Schaack J, Simon FR. Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1. Biochem J. 2004;378:919-928. [PMID: 14670077 DOI: 10.1042/bj20031587] [Cited by in Crossref: 114] [Cited by in F6Publishing: 122] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 291 |
Friedman JS, Lopez MF, Fleming MD, Rivera A, Martin FM, Welsh ML, Boyd A, Doctrow SR, Burakoff SJ. SOD2-deficiency anemia: protein oxidation and altered protein expression reveal targets of damage, stress response, and antioxidant responsiveness. Blood. 2004;104:2565-2573. [PMID: 15205258 DOI: 10.1182/blood-2003-11-3858] [Cited by in Crossref: 110] [Cited by in F6Publishing: 119] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 292 |
Virtue MA, Furne JK, Ho SB, Levitt MD. Use of alveolar carbon monoxide to measure the effect of ribavirin on red blood cell survival. Am J Hematol 2004;76:107-13. [PMID: 15164374 DOI: 10.1002/ajh.20069] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 293 |
Smith JP, Riley TR 3rd, Devenyi A, Bingaman SI, Kunselman A. Amantadine therapy for chronic hepatitis C. J Gen Intern Med 2004;19:662-8. [PMID: 15209605 DOI: 10.1111/j.1525-1497.2004.30057.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 294 |
Grattagliano I, Russmann S, Palmieri VO, Jüni P, Bihl F, Portincasa P, Palasciano G, Lauterburg BH. Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C. Hepatology 2004;39:1248-55. [PMID: 15122753 DOI: 10.1002/hep.20208] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 295 |
Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004;11:243-50. [PMID: 15117326 DOI: 10.1111/j.1365-2893.2004.00490.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 90] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 296 |
Bräu N. Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C. J Viral Hepat 2004;11:191-7. [PMID: 15117320 DOI: 10.1111/j.1365-2893.2004.00506.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 297 |
Chan MH, Wong VW, Wong CK, Chan PK, Chu CM, Hui DS, Suen MW, Sung JJ, Chung SS, Lam CW. Serum LD1 isoenzyme and blood lymphocyte subsets as prognostic indicators for severe acute respiratory syndrome. J Intern Med 2004;255:512-8. [PMID: 15049886 DOI: 10.1111/j.1365-2796.2004.01323.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 298 |
Homma M, Matsuzaki Y, Inoue Y, Shibata M, Mitamura K, Tanaka N, Kohda Y. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol 2004;2:337-9. [PMID: 15067629 DOI: 10.1016/s1542-3565(04)00064-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 299 |
Afdhal NH. Role of epoetin alfa in maintaining ribavirin dose. Gastroenterol Clin North Am 2004;33:S25-35. [PMID: 15081101 DOI: 10.1016/j.gtc.2003.12.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 300 |
Manns MP. Adherence to combination therapy: influence on sustained virologic response and economic impact. Gastroenterol Clin North Am 2004;33:S11-24. [PMID: 15081100 DOI: 10.1016/j.gtc.2003.12.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 301 |
Gish RG. Treating hepatitis C: the state of the art. Gastroenterol Clin North Am 2004;33:S1-9. [PMID: 15081099 DOI: 10.1016/j.gtc.2003.12.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 302 |
Lunel-Fabiani F, Fouchard-Hubert I, Gergely AE. [Use of erythropoietin in the treatment of anemia induced by ribavirin/interferon in patients with hepatitis C]. Pathol Biol (Paris) 2003;51:520-4. [PMID: 14568602 DOI: 10.1016/s0369-8114(03)00169-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 303 |
Lindahl K, Schvarcz R, Bruchfeld A, Ståhle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004;11:84-7. [PMID: 14738562 DOI: 10.1046/j.1365-2893.2003.00475.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 304 |
Dev A, Patel K, Mc Hutchison JG. Current standard of care in hepatitis C virus infection. Hepatitis Prevention and Treatment 2004. [DOI: 10.1007/978-3-0348-7903-3_8] [Reference Citation Analysis]
|
| 305 |
Ahmed F, Jacobson I. Hepatitis C. Atlas of the Liver 2004. [DOI: 10.1007/978-1-4615-6502-4_5] [Reference Citation Analysis]
|
| 306 |
Brugnara C. Sickle cell disease: from membrane pathophysiology to novel therapies for prevention of erythrocyte dehydration. J Pediatr Hematol Oncol 2003;25:927-33. [PMID: 14663274 DOI: 10.1097/00043426-200312000-00004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 307 |
Dev A, Patel K, Muir A, McHutchison JG. Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions. Am J Gastroenterol 2003;98:2344-7. [PMID: 14638332 DOI: 10.1111/j.1572-0241.2003.08696.x] [Reference Citation Analysis]
|
| 308 |
Dieterich DT, Wasserman R, Bräu N, Hassanein TI, Bini EJ, Bowers PJ, Sulkowski MS. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003;98:2491-9. [PMID: 14638354 DOI: 10.1111/j.1572-0241.2003.08700.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 42] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 309 |
Shiffman ML, Vargas HE, Everson GT. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transpl 2003;9:1129-44. [PMID: 14586872 DOI: 10.1053/jlts.2003.50261] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 310 |
Ohsawa I, Uehara Y, Hashimoto S, Endo M, Fujita T, Ohi H. Autoimmune hemolytic anemia occurred prior to evident nephropathy in a patient with chronic hepatitis C virus infection: case report. BMC Nephrol 2003;4:7. [PMID: 12946280 DOI: 10.1186/1471-2369-4-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 311 |
Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003;37:533-41. [PMID: 12905138 DOI: 10.1086/376971] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 312 |
Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003;124:1711-9. [PMID: 12761728 DOI: 10.1016/s0016-5085(03)00394-9] [Cited by in Crossref: 197] [Cited by in F6Publishing: 210] [Article Influence: 9.9] [Reference Citation Analysis]
|
| 313 |
Hong Z, Cameron CE. Pleiotropic mechanisms of ribavirin antiviral activities. Prog Drug Res 2002;59:41-69. [PMID: 12458963 DOI: 10.1007/978-3-0348-8171-5_2] [Cited by in Crossref: 60] [Cited by in F6Publishing: 67] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 314 |
Tseng C, Laughlin C. Antiviral Agents, RNA Viruses (Other than HIV), and Orthopoxviruses. Burger's Medicinal Chemistry and Drug Discovery 2003. [DOI: 10.1002/0471266949.bmc083] [Reference Citation Analysis]
|
| 315 |
Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected patient. Clin Liver Dis 2003;7:179-94. [PMID: 12691466 DOI: 10.1016/s1089-3261(02)00074-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 316 |
Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med 2003;34:1-10. [PMID: 12498974 DOI: 10.1016/s0891-5849(02)01167-x] [Cited by in Crossref: 317] [Cited by in F6Publishing: 327] [Article Influence: 15.9] [Reference Citation Analysis]
|
| 317 |
Fabris P, Tositti G, Giordani MT, De Lalla F. Successfull response to alpha 2b interferon plus ribavirin associated with venesectomies in a patient with chronic hepatitis C and genetic hemochromatosis. J Gastroenterol Hepatol 2003;18:116-7. [PMID: 12519239 DOI: 10.1046/j.1440-1746.2003.02940.x] [Reference Citation Analysis]
|
| 318 |
Mangoni ED, Marrone A, Saviano D, Vecchio CD, Utili R, Ruggiero G. Normal Erythropoietin Response in Chronic Hepatitis C Patients with Ribavirin-Induced Anaemia. Antiviral Therapy 2003;8:57-63. [DOI: 10.1177/135965350300800108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 319 |
Fang C, Srivastava P, Lin C. Effect of ribavirin, levovirin and viramidine on liver toxicological gene expression in rats. J Appl Toxicol 2003;23:453-9. [DOI: 10.1002/jat.938] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 320 |
Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237-44. [PMID: 12407599 DOI: 10.1053/jhep.2002.36810] [Cited by in Crossref: 65] [Cited by in F6Publishing: 220] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 321 |
Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36:S237-44. [PMID: 12407599 DOI: 10.1053/jhep.2002.36810] [Cited by in Crossref: 331] [Cited by in F6Publishing: 295] [Article Influence: 15.8] [Reference Citation Analysis]
|
| 322 |
Gane E. Treatment of recurrent hepatitis C. Liver Transpl 2002;8:S28-37. [PMID: 12362295 DOI: 10.1053/jlts.2002.35860] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 323 |
Chang CH, Chen KY, Lai MY, Chan KA. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1623-32. [PMID: 12197841 DOI: 10.1046/j.1365-2036.2002.01326.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 324 |
Gaeta GB, Precone DF, Felaco FM, Bruno R, Spadaro A, Stornaiuolo G, Stanzione M, Ascione T, De Sena R, Campanone A, Filice G, Piccinino F. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1633-9. [PMID: 12197842 DOI: 10.1046/j.1365-2036.2002.01331.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 325 |
Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W, Gangl A, Ferenci P. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002;123:141-51. [PMID: 12105843 DOI: 10.1053/gast.2002.34175] [Cited by in Crossref: 98] [Cited by in F6Publishing: 100] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 326 |
Gergely AE, Lafarge P, Fouchard-Hubert I, Lunel-Fabiani F. Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C. Hepatology 2002;35:1281-2. [PMID: 11981781 DOI: 10.1053/jhep.2002.32529] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 327 |
Gluud LL, Krogsgaard K, Gluud C; Cochrane Hepato-Biliary Group. Ribavirin with or without alpha interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd002234.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 328 |
Pockros PJ. Developments in the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2002;11:515-28. [PMID: 11922860 DOI: 10.1517/13543784.11.4.515] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 329 |
Jeffries D. Antiviral drugs. Side Effects of Drugs Annual 2002. [DOI: 10.1016/s0378-6080(02)80036-8] [Reference Citation Analysis]
|
| 330 |
Ballas SK. Sickle cell anaemia: progress in pathogenesis and treatment. Drugs 2002;62:1143-72. [PMID: 12010077 DOI: 10.2165/00003495-200262080-00003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 331 |
Neuman MG, Blendis LM, Shear NH, Malkiewicz IM, Ibrahim A, Katz GG, Sapir D, Halpern Z, Brill S, Peretz H, Magazinik S, Konikoff FM. Cytokine network in nonresponding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate. Clin Biochem 2001;34:183-8. [PMID: 11408015 DOI: 10.1016/s0009-9120(01)00213-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 332 |
Neuman MG, Benhamou JP, Malkiewicz IM, Akremi R, Shear NH, Asselah T, Ibrahim A, Boyer N, Martinot-Peignoux M, Jacobson-Brown P, Katz GG, Le Breton V, Le Guludec G, Suneja A, Marcellin P. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin Biochem 2001;34:173-82. [PMID: 11408014 DOI: 10.1016/s0009-9120(01)00212-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 333 |
Targhetta S, Burra P, Popovic A, Silverj E, Pevere S, Russo FP, Zanus G, Cecchetto A, Naccarato R, Fagiuoli S. Natural alpha-IFN in HCV recurrence after liver transplantation. Transplant Proc 2001;33:1457-8. [PMID: 11267371 DOI: 10.1016/s0041-1345(00)02811-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 334 |
Brugnara C. Therapeutic Strategies for Prevention of Sickle Cell Dehydration. Blood Cells, Molecules, and Diseases 2001;27:71-80. [DOI: 10.1006/bcmd.2000.0366] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 335 |
Smee DF, Bailey KW, Sidwell RW. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir. Antivir Chem Chemother 2000;11:303-9. [PMID: 10950392 DOI: 10.1177/095632020001100406] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 336 |
. Current Awareness. Pharmacoepidem Drug Safe 2000;9:441-56. [DOI: 10.1002/1099-1557(200009/10)9:5<441::aid-pds491>3.0.co;2-b] [Reference Citation Analysis]
|
| 337 |
Aljofan M, Lo MK, Rota PA, Michalski WP, Mungall BA. Off Label Antiviral Therapeutics for Henipaviruses: New Light Through Old Windows. J Antivir Antiretrovir 2010;2:1-10. [PMID: 20668647 DOI: 10.4172/jaa.1000014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
|
